Lumida
/UTHR
⌘K
United Therapeutics Corp

United Therapeutics Corp

UTHR
$497.11USD-1.34%-6.75 today

MARKET CAP

21.3B

P/E (TTM)

18.0x

FWD P/E

18.7x

DAY RANGE

$496 – $509

52W RANGE

$395
$609

AI Summary

Stalk
StalkMedium

UTHR remains in a corrective pullback below declining EMAs into oversold extremes within its broader uptrend. Mean-reversion eligibility grants a medium-term bullish bias, but short-term timing disfavors entry until price demonstrates support acceptance near the 480–490 zone. Execution is deferred pending clear pullback absorption.

  • Pipeline catalysts: Rilinopag & nebulized Tyveso could unlock multi-$B revenues pending 2027 approvals
  • Q2 EPS grew to $7.27 from $6.41 YoY despite flat $783M revenues
  • Q2 revenue was flat at $783M YoY, showing limited top-line growth
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.7B$1.9B$2.3B$2.9B$3.2B
YoY %+13.6%+14.9%+20.2%+23.6%+10.6%
P / Sales6.1x6.8x4.9x5.9x7.3x
EV / Sales6.3x7.0x4.8x5.7x7.1x
Gross Profit, Adj.$1.6B$1.8B$2.1B$2.6B$2.8B
YoY %+13.7%+14.2%+16.0%+24.0%+9.0%
Margin %92.7%92.2%88.9%89.2%87.9%
EV / Gross Profit6.7x7.6x5.4x6.4x8.1x
EBITDA, Adj.$605.8M$1.0B$1.2B$1.4B$1.6B
YoY %-5.9%+70.2%+20.1%+17.1%+8.9%
Margin %35.9%53.2%53.2%50.4%49.6%
EV / EBITDA17.4x13.1x9.1x11.3x14.3x
EBIT$553.6M$978.0M$1.2B$1.4B$1.5B
YoY %-5.3%+76.7%+21.2%+16.2%+8.4%
Margin %32.8%50.5%50.9%47.9%46.9%
EV / EBIT19.0x13.8x9.5x11.9x15.1x
Net Income$475.8M$727.3M$984.8M$1.2B$1.3B
YoY %-7.6%+52.9%+35.4%+21.4%+11.7%
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (GAAP)$10.06$15.00$19.81$24.64$27.86
YoY %-12.8%+49.1%+32.1%+24.4%+13.1%